CTOs on the Move

NCS PHARMACEUTICALS

www.ncspharma.com

 
NCS PHARMACEUTICALS is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ncspharma.com
  • 2 Executive Dr Ste 100
    Somerset, NJ USA 08873
  • Phone: 732.805.9977

Executives

Name Title Contact Details

Similar Companies

Venture Technology Group

Venture Technology Group is a Farmington Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wheeler Pharmacy

Wheeler Pharmacy is a Lanett, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProUroCare

ProUroCare is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lupin

Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.